David Kerr
Fondateur chez Oxford Cancer Biomarkers Ltd.
Profil
David Kerr is the founder of Oxford Cancer Biomarkers Ltd.
(founded in 2012) and holds the title of Director.
He is currently working as a Director & Chief Medical Officer at Ingenox Therapeutics Ltd., a Researcher at the University of Oxford, Chief Medical Officer at Celleron Therapeutics Ltd., and Principal at OxOnc Development LP.
Postes actifs de David Kerr
| Sociétés | Poste | Début |
|---|---|---|
OxOnc Development LP
 OxOnc Development LP BiotechnologyHealth Technology OxOnc Development LP operates as an oncology development company. It offers a drug development model that is based on the expertise and core competencies to design and execute clinical trials in oncology. The firm's business model is an integration of scientific, clinical, operational and financial resources, and provides a value-add proposition to its co-development partner by providing a profit and loss-sparing mechanism to fund research and development efforts externally. The company was founded in 2012 and is headquartered in George Town, Cayman Islands. | Corporate Officer/Principal | - |
| University of Oxford | Corporate Officer/Principal | - |
Oxford Cancer Biomarkers Ltd.
 Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | Fondateur | 01/01/2012 |
Celleron Therapeutics Ltd.
 Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | Directeur Technique/Scientifique/R&D | - |
Ingenox Therapeutics Ltd.
 Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | Directeur Technique/Scientifique/R&D | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
OxOnc Development LP
OxOnc Development LP BiotechnologyHealth Technology OxOnc Development LP operates as an oncology development company. It offers a drug development model that is based on the expertise and core competencies to design and execute clinical trials in oncology. The firm's business model is an integration of scientific, clinical, operational and financial resources, and provides a value-add proposition to its co-development partner by providing a profit and loss-sparing mechanism to fund research and development efforts externally. The company was founded in 2012 and is headquartered in George Town, Cayman Islands. | Health Technology |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | Health Services |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | Health Technology |
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | Health Services |